The Corner Series Episode 116: What’s Next in the Psychedelics Market, With Matt Brockmeier and Rebecca Nicholson
Nov 19, 2025
Join Matt Brockmeier, co-founder of Emtheogen and legal expert on psychedelics, and Rebecca Nicholson, director at Prime Quadrant with a passion for wellness investing, as they dive into the intriguing world of psychedelics. They explore the ongoing legal tensions between state and federal regulations, and Rebecca highlights the unique investment opportunities in psychedelics versus cannabis. The duo also discusses the medical community's cautious embrace, the need for innovative research, and the supportive wellness practices enhancing psychedelic care.
AI Snips
Chapters
Transcript
Episode notes
State Versus Federal Tension Shapes Access
- U.S. psychedelics policy is defined by a state-vs-federal tension that mirrors cannabis legalization history.
- States like Colorado and Alaska are moving ahead while federal law lags, creating uneven access and markets.
Therapeutic Framing Distinguishes Psychedelics
- Psychedelics differ from cannabis because they're framed around mental health rather than recreation, changing investor and regulatory dynamics.
- Rebecca views psychedelics as a long-term therapeutic relationship, not a quick speculative play.
Target State-Regulated Markets First
- Focus investor attention on jurisdictions with state-level regulated models like Colorado, Oregon and New Mexico for earlier market opportunities.
- Prioritize state-regulated access models to offer lower-cost, practical routes to treatment versus high-cost pharma development.